Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway.

ABSTRACT:

Objective

Given the limitations of current anti-resorption agents for postmenopausal osteoporosis, there is a need for alternatives without impairing coupling crosstalk between bone resorption and bone formation ie. osteoclastogenesis. Puerarin, a unique C-glycoside isoflavonoid, was found to be able to prevent bone loss by inhibiting bone resorption, but the underlying mechanism was controversial. In this study, we investigated the effects of puerarin on osteoclastic differentiation, activation and bone resorption and its underlying molecular mechanism in vitro, and then evaluated the effects of puerarin on bone metabolism using an ovariectomized (OVX) rat model.

Methods

In vitro, the effect of puerarin on osteoclastic cytotoxicity, differentiation, apoptosis,

SUBMITTER: Qiu Z 

PROVIDER: S-EPMC8858883 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature